Tetralone-based monoamine reuptake inhibitors

A compound having a structure, which is selected from Formula (II), Formula (III), and Formula (IV), or a pharmaceutically acceptable salt thereof:

• wherein
• n is an integer selected from 0 to 2;
• D is CX—Ar1;
• m is an integer selected from 0 to 6;
• each X is independently selected from H, halogen, CN, OR5, SR5, S(O)2R5, NR6R7, NR6S(O)2R5, NR6C(O)R5, acyl, ═X1, substituted or unsubstituted alkyl except CF3, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl,
• wherein
• X1 is selected from O, S, and NOR5′ wherein R5′ is selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl;
• each R5, R6 and R7 is independently selected from H, acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl,
• wherein two of R5, R6 and R7, together with the atoms to which they are attached, are optionally joined to form a 3- to 7-membered ring;
• Ar1 is
• wherein
• Y and Z are each independently Cl, CF3, or CN;
• V and W are independently selected from H, halogen, CF3, CN, OR9, SR9, S(O)2R9, NR10R11, NR10S(O)2R9, NR10C(O)R9, acyl, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl, or
• V and W, together with the atoms to which they are attached, are joined to form a 5- to 7-membered ring;
• wherein each R9, R10, and R11 is independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl;
• wherein any two of R9, R10, and R11, together with the atoms to which they are attached, are optionally joined to form a 3- to 7-membered ring;
• each R1 and R2 is independently selected from H, halogen, CN, CF3, OR12, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl,
• wherein
• R12 is selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl;
• R3 and R4 are independently selected from H, OR13, acyl, S(O)2R14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl,
• wherein
• R13 is selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl;
• R14 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl;
• and
• wherein at least two of R1, R2, R3 and R4, together with the atoms to which they are attached, are optionally joined to form a 3- to 7-membered ring,
• and any enantiomer, diastereoisomer, racemic mixture, enantiomerically enriched mixture, and enantiomerically pure form thereof